You are here

THE DEVELOPMENT OF A SENSITIVE, RAPID, AND RELATIVELY INEXPENSIVE SERUM ASSAY FOR SPECIFIC FORMS OF CANCER WOULD BE INVALUABLE FOR THE EARLY DIAGNOSIS OF THE CANCER, ITS SUBSEQUENT TREATMENT, AND STUDIES ON THE ETIOLOGY AND EPIDEMIOLOGY OF THE DISEASE.

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 1386
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1984
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
P.o. Box 1560
Davis, CA 95617
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JAMES L. HILLMAN
 DIRECTOR
 () -
Business Contact
Phone: () -
Research Institution
N/A
Abstract

THE DEVELOPMENT OF A SENSITIVE, RAPID, AND RELATIVELY INEXPENSIVE SERUM ASSAY FOR SPECIFIC FORMS OF CANCER WOULD BE INVALUABLE FOR THE EARLY DIAGNOSIS OF THE CANCER, ITS SUBSEQUENT TREATMENT, AND STUDIES ON THE ETIOLOGY AND EPIDEMIOLOGY OF THE DISEASE. WHILE NOT A DIAGNOSTIC PANACEA, THE SERUM ASSAY COULD QUICKEN DIAGNOSIS AND AID IN FOLLOW-UP ON THE PROGRESSION OR REGRESSION OF THE NEOPLASM. IN THIS PROPOSAL WE PLAN TO DEVELOP AN IMMUNOCHEMICAL ASSAY FOR HUMAN SERUM EPOXIDE HYDROLASE-PRENEOPLASTIC ANTIGEN IN ORDER TO FACILITATE STUDIES ON THIS ASSAY AS A SPECIFIC TEST FOR HEPATO-CELLULAR CARCINOMA IN HUMANS (PHASE I). THE NUMBER ONE CAUSE OF DEATH FROM CANCER, LIVER CANCER HAS AN ETIOLOGICALLY PREDISPOSING POPULATION OF MILLIONS WHO SUFFER FROM HEPATITIS B, CIRRHOSIS, AND OTHER CHRONIC LIVER DISEASES. BASED ON STUDIES IN FARBER'S GRIFFIN'S AND LEVIN'S LABORATORIES A PROTEIN EH-PNA (EPOXIDE HYDROLASE-PRENEOPLASTIC ANTIGEN) HAS BEEN DESCRIBED WHICH IS RELEASED FROM ITS MEMBRANOUS ENVIRONMENT SPECIALLY IN PRENEOPLASTIC AND NEOPLASTIC LIVER CELLS OF RODENTS. A SENSITIVE RADIOCHEMICAL ASSAY FOR EH-PNA DEVELOPED IN HAMMOCK'S LABORATORY (UNIVERSITY OF CALIFORNIA) HAS NOW PROVIDED EVIDENCE THAT ELEVATED EH-PNA APPEARS IN THE SERUM OF PATIENTS WITH HEPATO-CELLULAR CARCINOMA. USING ANTIBODIES AGAINST RAT EPOXIDE HYDROLASE A RAPID ENZYME-LINKED-IMMUNOABSORBENT-ASSAY (ELISA) HAS BEEN DEVELOPED DEMONSTRATING THE APPLICABILITY OF THIS TECHNIQUE FOR MEASURING EH-PNA. THE PURPOSE OF PHASE I OF THIS PROPOSAL IS TO DEVELOP AN IMMUNOCHEMICAL ASSAY FOR EH-PNA IN HUMAN SERUM. THIS ASSAY SHOULD BE OF PRIMARY INTEREST TO THE DIVISION OF CANCER BIOLOGY AND DIAGNOSIS, NATIONAL CANCER INSTITUTE. IT WILL INVOLVE WORK UNDER A LICENSING AGREEMENT ON AN INVENTION BY THE UNIVERSITY OF CALIFORNIA (THE MEASUREMENT OF SERUM EH-PNA) FOR WHICH A PATENT APPLICATION HAS BEEN MADE. THIS WILL ALLOW A SMALL BUSINESS IN CALIFORNIA TO PURSUE SPECIFIC RESEARCH THAT MAY LEAD EVENTUALLY TO THE RIGHTS FOR PRODUCTION AND MARKETING OF THE ASSAY KIT. COLLABORATION WITH THE UNIVERSITY OF CALIFORNIA WILL OCCUR ON SCIENTIFIC ASPECTS OF THE ASSAY. THE SPECIFIC AIMS FOR PHASE I ARE: 1) TO ISOLATE EH-PNA FROM LIVER MICROZOMES OF A PRIMATE, 2) TO USE THE ISOLATED EH-PNA AS AN ANTIGEN TO INDUCE ANTISERA IN GOATS AND RABBITS, 3) TO MAKE THE ANTISERA (IGG FRACTION) MONO-SPECIFIC FOR EH-PNA, AND 4) TO DEVELOP AN ELISA FOR EH-PNA APPLICABLE TO HUMAN SERA. THE KIT WOULD THEN BE DISTRIBUTED FOR USE IN STUDIES ON THE EFFICIENCY OF THE ASSAY WHICH WILL PROVIDE THE BASIS FOR PHASE II OF THIS PROJECT.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government